Voya Investment Management LLC Sells 142,493 Shares of Inspire Medical Systems, Inc. $INSP

Voya Investment Management LLC lessened its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 79.9% in the 3rd quarter, HoldingsChannel reports. The fund owned 35,826 shares of the company’s stock after selling 142,493 shares during the period. Voya Investment Management LLC’s holdings in Inspire Medical Systems were worth $2,658,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dragoneer Investment Group LLC grew its holdings in Inspire Medical Systems by 81.4% in the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock worth $305,532,000 after purchasing an additional 1,056,808 shares during the last quarter. Wasatch Advisors LP lifted its holdings in shares of Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Inspire Medical Systems by 214.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,112,925 shares of the company’s stock worth $177,267,000 after purchasing an additional 759,090 shares in the last quarter. State Street Corp grew its stake in Inspire Medical Systems by 2.3% during the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after buying an additional 22,843 shares during the last quarter. Finally, William Blair Investment Management LLC increased its position in Inspire Medical Systems by 11.0% during the 2nd quarter. William Blair Investment Management LLC now owns 769,169 shares of the company’s stock valued at $99,815,000 after buying an additional 76,251 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on INSP. JPMorgan Chase & Co. raised their price target on Inspire Medical Systems from $82.00 to $118.00 and gave the stock a “neutral” rating in a report on Tuesday, December 16th. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, October 27th. Morgan Stanley reissued an “equal weight” rating and set a $130.00 target price (up previously from $105.00) on shares of Inspire Medical Systems in a research report on Tuesday, December 2nd. Robert W. Baird upped their price target on shares of Inspire Medical Systems from $125.00 to $180.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Finally, UBS Group raised their price target on shares of Inspire Medical Systems from $89.00 to $91.00 and gave the stock a “neutral” rating in a report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $139.00.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the sale, the director directly owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. This trade represents a 7.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.10% of the company’s stock.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Neutral Sentiment: Comparative analysis of Inspire vs. Omnicell provides an investing viewpoint but does not change the immediate legal risk profile. Which Is a Better Investment, Inspire Medical Systems Inc. or Omnicell Inc. Stock?
• Negative Sentiment: Hagens Berman highlights a >32% stock crash after the reported “Inspire V” launch failure and urges affected investors to contact the firm — underscores the claimed link between product launch problems and investor losses. Inspire Medical (INSP) Crashes Over 32%, “Inspire V” Launch Failure
• Negative Sentiment: Faruqi & Faruqi announced an investigation into potential claims on behalf of INSP investors, encouraging contact from those who suffered losses. Faruqi & Faruqi Investigation
• Negative Sentiment: The Schall Law Firm and several other firms (Levi & Korsinsky, Rosen, Bronstein, BFA, Bleichmar) have filed or are soliciting lead-plaintiff roles in a securities suit alleging violations for the period Aug 6, 2024–Aug 4, 2025; many set a Jan 5, 2026 lead-plaintiff deadline. Schall Law Firm Notice
• Negative Sentiment: Levi & Korsinsky and Rosen Law Firm issued reminders about the pending class action and the Jan 5 lead-plaintiff deadline, increasing the likelihood multiple plaintiffs will consolidate claims. Levi & Korsinsky Reminder
• Negative Sentiment: Bleichmar Fonti & Auld and Bronstein, Gewirtz & Grossman publicized filings and notices after the stock drop, signaling multiple coordinated plaintiff actions and growing litigation exposure. BFA Law Notice
• Negative Sentiment: Local and national notices (e.g., Caledonian Record) reiterate the wave of litigation outreach — amplifies negative publicity and potential reputational harm. Caledonian Record Notice

Inspire Medical Systems Trading Down 0.3%

Shares of NYSE:INSP opened at $95.37 on Friday. Inspire Medical Systems, Inc. has a twelve month low of $70.77 and a twelve month high of $216.01. The company’s 50 day moving average is $101.36 and its 200 day moving average is $102.06. The company has a market cap of $2.77 billion, a PE ratio of 64.87, a price-to-earnings-growth ratio of 10.94 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.15) by $0.53. The business had revenue of $224.50 million during the quarter, compared to analysts’ expectations of $220.39 million. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.60 EPS. Equities research analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.